IL17A and cancer: In a prior study, IL-17 triggered the PD-1 pathway in cancer cells creating an immunosuppressive microenvironment (Wang et al., 2017) dominated by Treg cells whereas CD4 and Cd8 cells were inhibited (Ma et al., 2017).